PAID ADVERTISEMENT
Systemic inflammation plays a central role in the pathogenesis of atherosclerotic cardiovascular disease (ASCVD), particularly among patients with chronic kidney disease (CKD), and represents a significant contributor to residual risk among patients living with these comorbid conditions. Novel and emerging treatment options seek to target this residual risk; however, their integration into clinical care is challenged by suboptimal assessment of inflammatory risk in practice. For example, while high-sensitivity C-reactive protein (hsCRP) is a valuable biomarker for quantifying residual inflammatory risk, it is significantly underutilized in real-world care. In this interactive symposium, expert faculty will seamlessly integrate real-world case vignettes with cutting-edge clinical data and panel discussions to highlight evolving considerations for the role of systemic inflammation in ASCVD and CKD; underscore the potential for emerging inflammation-targeted strategies, such as interleukin-6 inhibition, to address residual risk; and explore practical strategies to optimize the assessment of residual inflammatory risk in practice.
Click here for more information.
This event is not part of the official Scientific Sessions 2025 as planned by the AHA Committee on Scientific Sessions Programming.